New cell therapy facility at Leiden Bio Science Park
American pharmaceutical company Bristol Myers Squibb will be building a new (CAR-T) cell therapy facility in the Oegstgeest part of the Leiden Bio Science Park. The company will manufacture and develop CAR T-cell therapy for patients with blood cancer (leukaemia), for example.
American pharmaceutical company Bristol Myers Squibb (BMS) and Leiden University – the owner of the land – signed a ground lease on 16 April 2021 for the site on Willem Einthovenweg where the new facility will be built. The company will not only bring knowledge development and therapies to the Leiden region but will also create an expected 500 new jobs.
Further information on the website Leiden University.